metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

breast cancer - triple negative
breast cancer - triple negative metastatic
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1) 3
mBC - TNBC - L1 - all population 7
mBC - TNBC - L1 - PDL1 positive 5
mBC-Triple negative (TNBC) - 2nd Line (L2) 3
mBC - TNBC - L2 - all population 2
mBC - TNBC - L2 - PDL1 positive 2
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) 1
es-BC - TNBC - NA - all population 6
es-BC - TNBC - NA - PDL1 positive 1
es-BC - Triple negatif (TNBC) - 1st line (L1)

All treatments
AKT inhibitor
capivasertib based treatment
capivasertib plus paclitaxel
ipatasertib based treatment
ipatasertib plus paclitaxel
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus nab-paclitaxel
atezolizumab plus paclitaxel
pembrolizumab based treatment
pembrolizumab plus SoC
poly ADP-ribose polymerase (PARP) inhibitor
veliparib plus paclitaxel plus carboplatin

versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open